Grifols, S.A. (NASDAQ:GRFS) Given Average Rating of “Hold” by Analysts

Shares of Grifols, S.A. (NASDAQ:GRFS) have earned an average recommendation of “Hold” from the five brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $10.00.

Several research firms recently issued reports on GRFS. JPMorgan Chase & Co. cut their target price on Grifols from $10.30 to $10.00 and set a “neutral” rating on the stock in a research report on Monday, December 8th. Zacks Research lowered Grifols from a “hold” rating to a “strong sell” rating in a report on Friday, December 5th. Wall Street Zen upgraded Grifols from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Grifols in a research report on Wednesday, October 8th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of GRFS. Royal Bank of Canada increased its holdings in Grifols by 21.7% in the 1st quarter. Royal Bank of Canada now owns 486,824 shares of the biotechnology company’s stock worth $3,461,000 after acquiring an additional 86,768 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Grifols during the first quarter worth about $184,000. Goldman Sachs Group Inc. increased its stake in shares of Grifols by 1.9% during the first quarter. Goldman Sachs Group Inc. now owns 4,212,032 shares of the biotechnology company’s stock worth $29,948,000 after purchasing an additional 80,507 shares in the last quarter. Ballentine Partners LLC raised its position in shares of Grifols by 48.9% during the 2nd quarter. Ballentine Partners LLC now owns 16,179 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 5,311 shares during the last quarter. Finally, Ascent Group LLC purchased a new position in Grifols in the 2nd quarter valued at about $141,000.

Grifols Price Performance

Shares of GRFS opened at $8.89 on Monday. The company has a 50 day moving average of $8.93 and a two-hundred day moving average of $9.51. The company has a quick ratio of 0.93, a current ratio of 2.48 and a debt-to-equity ratio of 1.20. Grifols has a twelve month low of $6.19 and a twelve month high of $11.14. The company has a market cap of $6.14 billion, a price-to-earnings ratio of 46.79, a price-to-earnings-growth ratio of 0.31 and a beta of 0.67.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.